OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Paner on HORIZON Trial in Multiple Myeloma

January 30th 2020

Agne Paner, MD, director, discusses the phase II HORIZON trial in relapsed/refractory multiple myeloma.

Dr. Hari on CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

January 30th 2020

Parameswaran Hari, MD, MRCP, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Dr. Bryce on Ongoing Research Regarding CDK12 Alterations in Prostate Cancer

January 30th 2020

Alan H. Bryce, MD, discusses ongoing research regarding CDK12 alterations in prostate cancer.

Dr. Shinohara on Toxicities of Stereotactic Body Radiotherapy in Prostate Cancer

January 30th 2020

Eric Shinohara, MD, MSCI, discusses the toxicities associated with stereotactic body radiotherapy in prostate cancer.

Dr. Oh on the ENZAMET Trial in mHSPC

January 30th 2020

William K. Oh, MD, discusses the phase III ENZAMET trial in metastatic hormone-sensitive prostate cancer.

Dr. Randall of Tumor Sequencing Research in Sarcomas

January 30th 2020

R. Lor Randall, MD, FACS, discusses ongoing research in sequencing the tumors of patients with primary bone or tissue sarcomas.

Dr. Hudson on the Rise of Liquid Biopsies in Lung Cancer

January 30th 2020

Kathryn E. Hudson, MD, discusses the rise of liquid biopsies as a tool for molecular testing in lung cancer.

Dr. Polsky on the Exploration of Blood-Based Biomarkers in Melanoma

January 30th 2020

David Polsky, MD, PhD, discusses the exploration of blood-based biomarkers in melanoma.

Dr. Coleman on the Use of Veliparib in Ovarian Cancer

January 29th 2020

Robert L. Coleman, MD, FACOG, FACS, professor and Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the use of veliparib in ovarian cancer.

Dr. Gonzalez-Martin on the Impact of the PRIMA Trial in Advanced Ovarian Cancer

January 29th 2020

Antonio Gonzalez-Martin, MD, co-director, Department of Medical Oncology, Clinica Universidad de Navarra, discusses the impact of the phase III PRIMA trial findings on clinical practice in advanced ovarian cancer.

Dr. Duska on the Utility of the Fagotti Score in Advanced Ovarian Cancer

January 29th 2020

Linda R. Duska, MD, professor of obstetrics and gynecology and gynecologic oncologist at the University of Virginia, explains whether the Fagotti score provides an accurate assessment of whether a patient with newly diagnosed, advanced ovarian cancer can achieve a complete resection in surgery.

Dr. Bahlis on Daratumumab Plus Lenalidomide and Dexamethasone in Multiple Myeloma

January 29th 2020

Nizar J. Bahlis, MD, discusses daratumumab (Darzalex) plus lenalidomide (Revlimid) and dexamethasone in newly diagnosed multiple myeloma.

Dr. Cowan on Efficacy and Safety of BCMA CAR T-Cells in Multiple Myeloma

January 29th 2020

Andrew J. Cowan, MD, discusses efficacy and safety of BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Dr. Borghaei on Immunotherapy versus Chemotherapy and Immunotherapy in NSCLC

January 29th 2020

Hossein Borghaei, DO, MS, discusses immunotherapy alone or in combination with chemotherapy in combination with immunotherapy in patients with advanced NSCLC.

Dr. Kremyanskaya on Effect of CPI-0610 in Patients With Myelofibrosis

January 29th 2020

Marina Kremyanskaya, MD, discusses the effect of CPI-0610 in patients with myelofibrosis.

Dr. Martin on Biomarker-Driven Therapeutics in Multiple Myeloma

January 29th 2020

Thomas G. Martin, MD, discusses biomarker-driven treatment options in multiple myeloma and currently available regimens.

Dr. Nasri on the Role of p16 and p21 as Predictive Biomarkers in Osteosarcoma

January 29th 2020

Elham Nasri, MD, discusses the role of p16 and p21 as predictive biomarkers in patients with osteosarcoma.

Dr. Aboulafia on Targeted Therapy in Tenosynovial Giant Cell Tumor

January 29th 2020

Albert J. Aboulafia, MD, discusses targeted therapy options in tenosynovial giant cell tumor.

Dr. Koo on the Actionability of Next-Generation Imaging Results in Prostate Cancer

January 29th 2020

Phillip J. Koo, MD, division chief of Diagnostic Imaging, Banner MD Anderson Cancer Center, discusses the actionability of next-generation imaging results in prostate cancer.

Dr. Bryce on Ongoing Research in Prostate Cancer

January 29th 2020

Alan H. Bryce, MD, assistant professor of medicine and medical director of the Genomic Oncology Clinic, Mayo Clinic, discusses ongoing research in prostate cancer.